Resources from the same session
LBA4 - Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
Presenter: Patrick Neven
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
165MO - Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
166MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase 1b/2 study
Presenter: Peter Schmid
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
167MO - Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
Presenter: Thibault de La Motte Rouge
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini Oral session 2
Resources:
Webcast